Akash Tewari
Stock Analyst at Jefferies
(2.50)
# 2,313
Out of 5,154 analysts
61
Total ratings
39.13%
Success rate
5.08%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $42.82 | -18.26% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $74.04 | +29.66% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $759.86 | +9.36% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $12.07 | +115.41% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $13.60 | -26.47% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $60.29 | +12.79% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $61.12 | +55.43% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $101.50 | +47.78% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $9.89 | +61.78% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $128.13 | +47.51% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $20.07 | +298.60% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $990.33 | +2.49% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $28.63 | +74.64% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $73.05 | +2.67% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $40.15 | -22.79% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $27.05 | +44.18% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.54 | +32.94% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $717.79 | -28.53% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $115.79 | +7.95% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $24.08 | -54.32% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.55 | +996.77% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $60.41 | +24.15% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $432.83 | -65.11% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $41.55 | -32.60% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $42.82
Upside: -18.26%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $74.04
Upside: +29.66%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $759.86
Upside: +9.36%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $12.07
Upside: +115.41%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $13.60
Upside: -26.47%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $60.29
Upside: +12.79%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $61.12
Upside: +55.43%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $101.50
Upside: +47.78%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $9.89
Upside: +61.78%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $128.13
Upside: +47.51%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $20.07
Upside: +298.60%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $990.33
Upside: +2.49%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $28.63
Upside: +74.64%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $73.05
Upside: +2.67%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $40.15
Upside: -22.79%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $27.05
Upside: +44.18%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.54
Upside: +32.94%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $717.79
Upside: -28.53%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $115.79
Upside: +7.95%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $24.08
Upside: -54.32%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.55
Upside: +996.77%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $60.41
Upside: +24.15%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $432.83
Upside: -65.11%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $41.55
Upside: -32.60%